{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyOhfbrZsjLEyDu333fOCKTi",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/frank-morales2020/MLxDL/blob/main/CRSPR_DEMO_LLM_DEEPSEEK.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "UcPgw68zm_HY",
        "outputId": "fc17716f-4b74-4ceb-eb90-50f9a5791302"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "üß¨ INITIALIZING 8-AGENT CRISPR DEMONSTRATION SYSTEM...\n",
            "\n",
            "üîÑ AVAILABLE SCENARIOS:\n",
            "1. Sickle Cell Treatment - Target: BCL11A\n",
            "2. Huntington Therapy - Target: HTT\n",
            "3. Cystic Fibrosis - Target: CFTR\n",
            "\n",
            "üéØ RUNNING 8-AGENT ANALYSIS: Sickle Cell Treatment\n",
            "Note: This will call 8 different specialized agents\n",
            "Total processing time: ~8-10 minutes...\n",
            "\n",
            "üöÄ STARTING 8-AGENT CRISPR DEMO\n",
            "üéØ Target: BCL11A | Disease: Sickle Cell Anemia\n",
            "============================================================\n",
            "üî¨ RESEARCH AGENT: Working...\n",
            "‚úÖ üî¨ RESEARCH complete (64.9s)\n",
            "\n",
            "üéØ DESIGN AGENT: Working...\n",
            "‚úÖ üéØ DESIGN complete (70.9s)\n",
            "\n",
            "‚öñÔ∏è ETHICS AGENT: Working...\n",
            "‚úÖ ‚öñÔ∏è ETHICS complete (71.8s)\n",
            "\n",
            "üß™ VALIDATION AGENT: Working...\n",
            "‚úÖ üß™ VALIDATION complete (77.5s)\n",
            "\n",
            "üìä CLINICAL AGENT: Working...\n",
            "‚úÖ üìä CLINICAL complete (77.5s)\n",
            "\n",
            "üåç REGULATORY AGENT: Working...\n",
            "‚úÖ üåç REGULATORY complete (77.6s)\n",
            "\n",
            "üí∞ COMMERCIAL AGENT: Working...\n",
            "‚úÖ üí∞ COMMERCIAL complete (77.8s)\n",
            "\n",
            "üîç SAFETY AGENT: Working...\n",
            "‚úÖ üîç SAFETY complete (77.7s)\n",
            "\n",
            "\n",
            "üìä 8-AGENT COMPREHENSIVE REPORT:\n",
            "======================================================================\n",
            "\n",
            "üî¨ RESEARCH AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a CRISPR research scientist, I will provide a detailed technical analysis of targeting the *BCL11A* gene for the treatment of Sickle Cell Disease (SCD).\n",
            "\n",
            "### **1. Gene Function: BCL11A as a Master Regulator of Fetal Hemoglobin**\n",
            "\n",
            "*   **Primary Function:** BCL11A (B-Cell Lymphoma/Leukemia 11A) is a zinc-finger transcription factor that functions as a critical repressor of fetal hemogl...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üéØ DESIGN AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a CRISPR design specialist, I will provide a complete, state-of-the-art gene editing system targeting the *BCL11A* gene for the treatment of Sickle Cell Disease (SCD). This design is based on current clinical strategies, particularly those used in successful trials like CTX001.\n",
            "\n",
            "### **CRISPR-Cas9 Gene Editing System for BCL11A in Sickle Cell Anemia**\n",
            "\n",
            "This system is designed to disru...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "‚öñÔ∏è ETHICS AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a bioethics expert, I will provide a balanced ethical assessment of the use of CRISPR-Cas9 gene editing for targeting the *BCL11A* gene in the treatment of Sickle Cell Anemia (SCA). This intervention, as exemplified by therapies like Casgevy (exa-cel), represents a paradigm shift in medicine and thus demands rigorous ethical scrutiny.\n",
            "\n",
            "### **Introduction: The Scientific Promise**\n",
            "\n",
            "Si...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üß™ VALIDATION AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a QC and Validation Specialist, here is a comprehensive validation framework for a BCL11A CRISPR-based therapy for Sickle Cell Anemia (SCA). This framework is designed to ensure the product's safety, identity, purity, potency, and quality from development through commercial release.\n",
            "\n",
            "---\n",
            "\n",
            "### **Comprehensive Validation Framework for BCL11A CRISPR Therapy in Sickle Cell Anemia**\n",
            "\n",
            "This...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üìä CLINICAL AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a Clinical Trial Design Expert, I present a comprehensive clinical development plan for a BCL11A-targeting CRISPR/Cas9 therapy (hereinafter referred to as \"CTX-001,\" a placeholder name) for the treatment of Sickle Cell Anemia (SCA).\n",
            "\n",
            "---\n",
            "\n",
            "### **Clinical Development Plan: CTX-001 (BCL11A-targeting CRISPR/Cas9 Therapy) for Sickle Cell Anemia**\n",
            "\n",
            "**Overall Strategy:** A focused, seamless...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üåç REGULATORY AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a Regulatory Affairs Specialist, here is a detailed, phase-wise compliance pathway for a BCL11A-targeting CRISPR/Cas9 therapy for Sickle Cell Anemia (SCA), incorporating specific strategies for FDA and EMA alignment.\n",
            "\n",
            "### **Executive Summary: Regulatory Positioning**\n",
            "\n",
            "BCL11A CRISPR therapy represents a transformative, potentially curative, autologous ex vivo gene-editing product. The...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üí∞ COMMERCIAL AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a Market Access and Commercialization Expert, I present a comprehensive business strategy for a BCL11A-targeting CRISPR/Cas9 therapy for Sickle Cell Disease (SCD).\n",
            "\n",
            "**Executive Summary:**\n",
            "This strategy outlines the commercialization of a one-time, potentially curative autologous cell therapy for SCD. The model is built on a high-value, outcomes-based pricing structure justified by si...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "üîç SAFETY AGENT SUMMARY:\n",
            "--------------------------------------------------\n",
            "Of course. As a Pharmacovigilance and Risk Management Specialist, here is a comprehensive and robust safety protocol for a BCL11A CRISPR-based gene therapy for Sickle Cell Anemia (SCA). This plan is designed to be proactive, risk-proportionate, and span the entire product lifecycle from clinical trials to post-market authorization.\n",
            "\n",
            "---\n",
            "\n",
            "### **Comprehensive Risk Management Plan (RMP) for BCL11A CR...\n",
            "\n",
            "======================================================================\n",
            "\n",
            "‚úÖ 8-AGENT DEMO COMPLETED!\n",
            "Comprehensive CRISPR therapy analysis generated by specialized agent team!\n"
          ]
        }
      ],
      "source": [
        "# EXPANDED 8-AGENT CRISPR DEMO SYSTEM\n",
        "import requests\n",
        "import json\n",
        "import time\n",
        "from typing import Dict, List\n",
        "from google.colab import userdata\n",
        "\n",
        "# Initialize API\n",
        "api_key = userdata.get(\"DEEPSEEK_API_KEY\")\n",
        "if not api_key:\n",
        "    raise ValueError(\"Please set DEEPSEEK_API_KEY in Colab Secrets\")\n",
        "\n",
        "class EightAgentCRISPRDemo:\n",
        "    def __init__(self, api_key: str):\n",
        "        self.api_key = api_key\n",
        "        self.base_url = \"https://api.deepseek.com/v1\"\n",
        "        self.headers = {\n",
        "            \"Authorization\": f\"Bearer {api_key}\",\n",
        "            \"Content-Type\": \"application/json\"\n",
        "        }\n",
        "\n",
        "        self.scenarios = {\n",
        "            '1': {'name': 'Sickle Cell Treatment', 'target': 'BCL11A', 'disease': 'Sickle Cell Anemia'},\n",
        "            '2': {'name': 'Huntington Therapy', 'target': 'HTT', 'disease': 'Huntington Disease'},\n",
        "            '3': {'name': 'Cystic Fibrosis', 'target': 'CFTR', 'disease': 'Cystic Fibrosis'}\n",
        "        }\n",
        "\n",
        "    def call_llm(self, prompt: str, model: str = \"deepseek-chat\") -> str:\n",
        "        \"\"\"Make actual LLM API call\"\"\"\n",
        "        payload = {\n",
        "            \"model\": model,\n",
        "            \"messages\": [{\"role\": \"user\", \"content\": prompt}],\n",
        "            \"temperature\": 0.7,\n",
        "            \"max_tokens\": 2000\n",
        "        }\n",
        "\n",
        "        try:\n",
        "            response = requests.post(\n",
        "                f\"{self.base_url}/chat/completions\",\n",
        "                headers=self.headers,\n",
        "                json=payload,\n",
        "                timeout=60\n",
        "            )\n",
        "            response.raise_for_status()\n",
        "            return response.json()[\"choices\"][0][\"message\"][\"content\"]\n",
        "        except requests.exceptions.Timeout:\n",
        "            return \"‚è∞ LLM timeout - please try again\"\n",
        "        except Exception as e:\n",
        "            return f\"‚ùå API Error: {str(e)}\"\n",
        "\n",
        "    # CORE AGENTS\n",
        "    def research_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a CRISPR research scientist, analyze {target} gene for {disease} treatment:\n",
        "        Provide SPECIFIC technical analysis covering gene function, disease mechanism,\n",
        "        optimal CRISPR strategy with rationale, specific genomic coordinates, and recent clinical evidence.\n",
        "        Be detailed and technical.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def design_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a CRISPR design specialist, create complete gene editing system for {target} in {disease}:\n",
        "        Provide ACTUAL design: specific 20nt guide RNA sequence with GC analysis,\n",
        "        Cas protein variant, delivery method, step-by-step protocol, and expected outcomes.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def ethics_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a bioethics expert, evaluate CRISPR for {target} in {disease}:\n",
        "        Provide BALANCED ethical assessment: risk-benefit analysis, regulatory pathways,\n",
        "        equity concerns, safety protocols, and recommendations.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    # NEW EXPANSION AGENTS\n",
        "    def validation_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a QC and Validation Specialist, design testing protocols for {target} CRISPR therapy in {disease}:\n",
        "\n",
        "        Provide COMPREHENSIVE validation framework:\n",
        "        1. ANALYTICAL DEVELOPMENT:\n",
        "           - Potency assays (editing efficiency, functional impact)\n",
        "           - Identity tests (sequencing methods, specificity confirmation)\n",
        "           - Purity assays (residual vector, process impurities)\n",
        "\n",
        "        2. RELEASE CRITERIA:\n",
        "           - Minimum editing efficiency thresholds\n",
        "           - Viability and sterility requirements\n",
        "           - Vector copy number limits\n",
        "\n",
        "        3. CHARACTERIZATION METHODS:\n",
        "           - NGS for on-target and off-target analysis\n",
        "           - Functional assays (protein expression, phenotypic readouts)\n",
        "           - Long-term stability studies\n",
        "\n",
        "        4. COMPARABILITY PROTOCOLS:\n",
        "           - Process change validation strategies\n",
        "           - Platform qualification methods\n",
        "\n",
        "        Be specific about acceptance criteria and testing methodologies.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def clinical_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a Clinical Trial Design Expert, create trial strategy for {target} CRISPR therapy in {disease}:\n",
        "\n",
        "        Design COMPLETE clinical development plan:\n",
        "        1. TRIAL DESIGN:\n",
        "           - Phase I/II/III objectives and endpoints\n",
        "           - Patient selection criteria and stratification\n",
        "           - Dosing regimen and escalation strategy\n",
        "\n",
        "        2. ENDPOINT SELECTION:\n",
        "           - Primary efficacy endpoints (clinical and biomarker)\n",
        "           - Secondary endpoints and exploratory biomarkers\n",
        "           - Safety monitoring parameters\n",
        "\n",
        "        3. PATIENT MANAGEMENT:\n",
        "           - Pre-conditioning regimens\n",
        "           - Cell collection and processing logistics\n",
        "           - Post-treatment monitoring schedule\n",
        "\n",
        "        4. DATA COLLECTION:\n",
        "           - Long-term follow-up requirements (15+ years)\n",
        "           - Real-world evidence collection strategy\n",
        "           - Patient-reported outcomes\n",
        "\n",
        "        Include specific enrollment numbers and timeline estimates.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def regulatory_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a Regulatory Affairs Specialist, outline FDA/EMA compliance pathway for {target} CRISPR therapy in {disease}:\n",
        "\n",
        "        Provide DETAILED regulatory strategy:\n",
        "        1. SUBMISSION REQUIREMENTS:\n",
        "           - IND/CTA application components\n",
        "           - Pre-IND meeting package preparation\n",
        "           - Orphan drug designation strategy\n",
        "\n",
        "        2. CMC SECTION:\n",
        "           - Chemistry, Manufacturing, Controls requirements\n",
        "           - Process validation expectations\n",
        "           - Stability data requirements\n",
        "\n",
        "        3. NON-CLINICAL REQUIREMENTS:\n",
        "           - Toxicology study design\n",
        "           - Biodistribution and persistence studies\n",
        "           - Tumorigenicity assessment\n",
        "\n",
        "        4. CLINICAL REGULATORY:\n",
        "           - Fast-track/Breakthrough Therapy designation potential\n",
        "           - Risk Evaluation and Mitigation Strategy (REMS)\n",
        "           - Post-marketing requirements\n",
        "\n",
        "        5. GLOBAL STRATEGY:\n",
        "           - EMA MAA parallel scientific advice\n",
        "           - Other major market regulatory pathways\n",
        "           - Pediatric investigation plan requirements\n",
        "\n",
        "        Be specific about timelines and agency interactions.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def commercial_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a Market Access and Commercialization Expert, develop business strategy for {target} CRISPR therapy in {disease}:\n",
        "\n",
        "        Create COMPREHENSIVE commercial plan:\n",
        "        1. MARKET ACCESS STRATEGY:\n",
        "           - Pricing model and value-based pricing justification\n",
        "           - Reimbursement pathway (US, EU, other markets)\n",
        "           - Health Technology Assessment preparation\n",
        "\n",
        "        2. MANUFACTURING & SUPPLY CHAIN:\n",
        "           - COGS analysis and production scaling strategy\n",
        "           - Supply chain logistics for autologous therapies\n",
        "           - Capacity planning and site selection\n",
        "\n",
        "        3. COMMERCIAL OPERATIONS:\n",
        "           - Treatment center qualification and training\n",
        "           - Patient identification and referral networks\n",
        "           - Hub services and patient support programs\n",
        "\n",
        "        4. MARKET DYNAMICS:\n",
        "           - Competitive landscape analysis\n",
        "           - Market size and penetration projections\n",
        "           - Launch sequence and geographic expansion\n",
        "\n",
        "        5. PATIENT ACCESS:\n",
        "           - Co-pay assistance programs\n",
        "           - Alternative funding mechanisms\n",
        "           - International access strategies for low-income regions\n",
        "\n",
        "        Include specific pricing recommendations and market projections.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def safety_agent(self, target: str, disease: str) -> str:\n",
        "        prompt = f\"\"\"\n",
        "        As a Pharmacovigilance and Risk Management Specialist, develop safety protocol for {target} CRISPR therapy in {disease}:\n",
        "\n",
        "        Create ROBUST risk management plan:\n",
        "        1. RISK IDENTIFICATION:\n",
        "           - Known risks (off-target effects, insertional mutagenesis)\n",
        "           - Theoretical risks (long-term clonal dominance, immunogenicity)\n",
        "           - Procedure-related risks (myeloablation, cell processing)\n",
        "\n",
        "        2. RISK MINIMIZATION:\n",
        "           - Targeted risk minimization activities\n",
        "           - Safety specification document\n",
        "           - Pharmacovigilance plan\n",
        "\n",
        "        3. SAFETY MONITORING:\n",
        "           - Short-term and long-term safety monitoring protocols\n",
        "           - Specific laboratory parameters to track\n",
        "           - Imaging and diagnostic monitoring schedule\n",
        "\n",
        "        4. RISK COMMUNICATION:\n",
        "           - Healthcare provider communication strategy\n",
        "           - Patient safety card and educational materials\n",
        "           - Periodic safety update reports\n",
        "\n",
        "        5. EMERGENCY PROTOCOLS:\n",
        "           - Management of adverse events\n",
        "           - Stopping rules for clinical trials\n",
        "           - Post-market safety surveillance\n",
        "\n",
        "        Include specific monitoring parameters and frequency.\n",
        "        \"\"\"\n",
        "        return self.call_llm(prompt)\n",
        "\n",
        "    def run_complete_demo(self, scenario_id: str):\n",
        "        \"\"\"Run all 8 agents for comprehensive analysis\"\"\"\n",
        "        if scenario_id not in self.scenarios:\n",
        "            return \"Invalid scenario\"\n",
        "\n",
        "        scenario = self.scenarios[scenario_id]\n",
        "        print(f\"üöÄ STARTING 8-AGENT CRISPR DEMO\")\n",
        "        print(f\"üéØ Target: {scenario['target']} | Disease: {scenario['disease']}\")\n",
        "        print(\"=\" * 60)\n",
        "\n",
        "        # All 8 agents\n",
        "        agents = [\n",
        "            (\"üî¨ RESEARCH\", self.research_agent),\n",
        "            (\"üéØ DESIGN\", self.design_agent),\n",
        "            (\"‚öñÔ∏è ETHICS\", self.ethics_agent),\n",
        "            (\"üß™ VALIDATION\", self.validation_agent),\n",
        "            (\"üìä CLINICAL\", self.clinical_agent),\n",
        "            (\"üåç REGULATORY\", self.regulatory_agent),\n",
        "            (\"üí∞ COMMERCIAL\", self.commercial_agent),\n",
        "            (\"üîç SAFETY\", self.safety_agent)\n",
        "        ]\n",
        "\n",
        "        results = {}\n",
        "        for agent_name, agent_func in agents:\n",
        "            print(f\"{agent_name} AGENT: Working...\")\n",
        "            start_time = time.time()\n",
        "\n",
        "            result = agent_func(scenario['target'], scenario['disease'])\n",
        "            results[agent_name] = result\n",
        "\n",
        "            elapsed = time.time() - start_time\n",
        "            print(f\"‚úÖ {agent_name} complete ({elapsed:.1f}s)\\n\")\n",
        "\n",
        "        # Display executive summary\n",
        "        print(\"\\nüìä 8-AGENT COMPREHENSIVE REPORT:\")\n",
        "        print(\"=\" * 70)\n",
        "        for agent_name, result in results.items():\n",
        "            print(f\"\\n{agent_name} AGENT SUMMARY:\")\n",
        "            print(\"-\" * 50)\n",
        "            # Show first 300 chars as preview\n",
        "            preview = result[:400] + \"...\" if len(result) > 400 else result\n",
        "            print(preview)\n",
        "            print(\"\\n\" + \"=\" * 70)\n",
        "\n",
        "        return results\n",
        "\n",
        "# Execute the expanded 8-agent demo\n",
        "print(\"üß¨ INITIALIZING 8-AGENT CRISPR DEMONSTRATION SYSTEM...\\n\")\n",
        "\n",
        "# Create demo instance\n",
        "demo = EightAgentCRISPRDemo(api_key)\n",
        "\n",
        "# Show available scenarios\n",
        "print(\"üîÑ AVAILABLE SCENARIOS:\")\n",
        "for id, scenario in demo.scenarios.items():\n",
        "    print(f\"{id}. {scenario['name']} - Target: {scenario['target']}\")\n",
        "\n",
        "# Run complete 8-agent demo\n",
        "print(f\"\\nüéØ RUNNING 8-AGENT ANALYSIS: Sickle Cell Treatment\")\n",
        "print(\"Note: This will call 8 different specialized agents\")\n",
        "print(\"Total processing time: ~8-10 minutes...\\n\")\n",
        "\n",
        "results = demo.run_complete_demo('1')\n",
        "\n",
        "print(\"\\n‚úÖ 8-AGENT DEMO COMPLETED!\")\n",
        "print(\"Comprehensive CRISPR therapy analysis generated by specialized agent team!\")"
      ]
    }
  ]
}